Two New Phase II Trials Enter the IPF Pipeline as Research Activity Stays High
November 9 to 16, 2026 · Active week
This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.
The week in plain words
This week two brand new experimental drug trials opened for IPF patients, SYH9061 and ND-003, both in Phase II, meaning they are still being tested in humans and nothing is proven yet. A major data-collection study called the PaTH Cohort officially completed, closing a chapter on how doctors and patients track this disease together. IPF still has no cure, the approved drugs slow the scarring process but cannot undo damage that has already happened.
Where things stand now
IPF remains a serious, progressive lung disease with no cure. The scarring it causes is permanent. Two anti-fibrotic pills, pirfenidone and nintedanib, have been approved for years and slow progression. A newer approved option, Nerandomilast (brand name Jascayd), received FDA approval in October 2025 and also slows the disease by targeting a protein called PDE4B. Inhaled Treprostinil and Admilparant are in late Phase III testing and have shown positive results, but are not yet approved for IPF specifically. Everything else in the pipeline, including cell therapies, gene delivery, and senolytic treatments that target aging cells, is still experimental and years away from any patient's medicine cabinet.
The best option right now
For someone with IPF right now, the most up-to-date clinically established options are the three in the top tier. Nerandomilast (Jascayd) is the newest FDA-approved drug, approved October 2025, and works by calming inflammation and slowing the activation of scar-forming cells called fibroblasts. Inhaled Treprostinil is a strong candidate awaiting FDA filing in 2026, and Admilparant is in a large Phase III trial called ALOFT-IPF with promising signals. All of these slow the disease. None of them reverse existing lung scarring or cure IPF. The honest framing is: the best available medicine buys time and preserves lung function longer, it does not restore what has been lost. Anyone with IPF should speak with a specialist about which approved or trial option fits their specific situation.
How close are we to regeneration
Regrowing healthy lung tissue in IPF is a research goal, not an available treatment. The most advanced experimental ideas in this direction involve three approaches, all preclinical or early concept stage. First, uPAR-CAR-T therapy uses engineered immune cells to clear out the old, stuck cells (called senescent cells) that drive scarring. This exists only in animal studies so far. Second, a combination strategy pairs senolytics (drugs that remove senescent cells, including a duo called D and Q) with a protein called RSPO3 that encourages the lung's own stem-like cells, called AEC2 cells, to multiply and repair. This is still a concept being tested in labs. Third, AI knowledge graph tools are connecting findings from aging, cancer, and lung biology research to spot new targets faster. This week's study of the week (see below) added a meaningful new piece to the regeneration puzzle, showing that a specific cell type in the lung lining plays a bigger role in keeping lung tissue healthy than previously understood. We are still far from regeneration being available to patients.
Study of the week
The standout study this week, published in the journal Developmental Cell, comes from Yang, Mou, Li and colleagues. It looked at a cell type called mesothelial cells, which line the outside surface of the lung like a thin wrapper. Scientists used to think these cells were mostly passive bystanders. This study found that mesothelial cells are actually quite flexible, able to change their identity and behavior, and that this flexibility plays an important role in keeping the lung's physical properties (how stretchy and resilient it is) in balance. When things go wrong with this flexibility, it may contribute to fibrosis, the harmful scarring seen in IPF. When things go right, it may support regeneration and repair. This is early research and does not lead to a treatment yet, but it opens a new line of thinking about what goes wrong in IPF and what a future repair strategy might target.
What changed since last week
The PaTH Clinical Data Research Network IPF Cohort (NCT02407431) officially changed status from active to completed this week. This was a large observational study, meaning it tracked patients and collected data rather than testing a drug. Its completion means that dataset is now closed and available for researchers to analyze. Two genuinely new experimental trials appeared this week. SYH9061 (NCT07933133) is a Phase II randomized controlled trial, not yet recruiting, that will compare the drug against a placebo and an active control in adult IPF patients. ND-003 tablets (NCT07929948) entered Phase IIa and is enrolling by invitation only. Both are investigational drugs with no proven benefit yet.
Our own search for a cure this week
Every day, PF-Atlas runs its own discovery engine, a genetic-algorithm solver combined with an AI literature scan, that simulates cocktails of existing, already-known drugs, including medicines originally approved for other diseases, to search for combinations that might help IPF. This is our own software generating computer hypotheses, not findings from outside researchers, and none of these outputs are clinical evidence or proven treatments. This week the solver completed 22 combination simulations (cross-disease candidates: 0, standalone hypotheses: 0). The solver's top five candidate molecules flagged this week as worthy of further investigation are: inhaled Verteporfin (a drug already used in eye disease, here proposed as an inhaled agent to block a protein called YAP1 that drives fibrosis), a Claudin-18 and LRP5 bispecific antibody designed to activate repair pathways in the lung lining, IRF2BPL messenger RNA delivered by inhaled nanoparticles, NKX2 to 1 synthetic messenger RNA delivered by lipid nanoparticles to the lung, and an activating peptide targeting a growth factor receptor called BMPR1A to promote healthy lung cell signaling. The solver's current best-scoring simulated cocktail combines five components: a WNT pathway activator (RSPO3), an ECM remodeling inhibitor to soften scar tissue, a HOPX activator to encourage mature lung cell identity, a curcumin-derived compound targeting inflammation proteins TLR4 and NLRP3, and a miR-34a inhibitor to reduce signals that drive cell aging. The solver assigned this combination a simulated FVC (lung function) score of 99, which is a model output reflecting how well the combination performed in the simulation, not a clinical result. These are computer-generated hypotheses that our team uses to prioritize which ideas deserve laboratory testing next.
Inside the PF-Atlas lab
- Inhaled Verteporfin (YAP1 Transcriptional Inhibitor)
- Claudin-18 / LRP5 Bispecific Agonist Antibody (CLN-18.2×LRP5-Fc)
- IRF2BPL mRNA (Inhaled Nanoparticle-Encapsulated)
- NKX2 to 1 (TTF-1) Nebulized Synthetic mRNA (LNP-formulated)
- BMPR1A/ALK3-Selective Activating Peptide (e.g., AB215 or BMP2/4 chimeric variant)
Everything here is PF-Atlas computer model output, a hypothesis to guide researchers. It is not clinical evidence and not a treatment anyone can take.
Sources this week
- PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort · status: ACTIVE_NOT_RECRUITING → COMPLETED NCT02407431 on ClinicalTrials.gov ↗
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis · new trial NCT07933133 on ClinicalTrials.gov ↗
- A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary Fibrosis · new trial NCT07929948 on ClinicalTrials.gov ↗
- A multi-targeted, barrier-penetrating inhalable nanoplatform for simultaneous immunomodulation and antifibrotic therapy in idiopathic pulmonary fibrosis. · Materials today. Bio 2026 PMID 43034868 on PubMed ↗
- Pirfenidone exerts anti-inflammatory effects by inhibiting CXCL6 to alleviate idiopathic pulmonary fibrosis. · International immunopharmacology 2026 PMID 42759355 on PubMed ↗
- Multi-omics reveals the effects and mechanisms of Xinxue Granules against idiopathic pulmonary fibrosis through activating the cAMP/EPAC/CREB axis. · Journal of ethnopharmacology 2026 PMID 42302945 on PubMed ↗
- The Burden of Chronic Cough in Patients With Interstitial Lung Disease: a US Survey-Based Analysis of Its Effects on Daily Life and Emotional and Social Well-Being. · Chest 2026 PMID 43025804 on PubMed ↗
- Overcoming the Pulmonary Mucus Barrier in Inhaled Drug Delivery: A Disease-Driven Precision Nanomedicine Framework. · Acta biomaterialia 2026 PMID 43025677 on PubMed ↗
- Idiopathic pulmonary fibrosis: Five trials to watch. · Med (New York, N.Y.) 2026 PMID 43025400 on PubMed ↗
- Idiopathic pleuroparenchymal fibroelastosis diagnosed following the onset of left vocal cord paralysis: A case report. · American journal of otolaryngology 2026 PMID 43025207 on PubMed ↗
- Proteomic analysis reveals regional sex differences in healthy and fibrotic human lung. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 43021538 on PubMed ↗
- Obstructive Sleep Apnea, Ferroptosis, and Idiopathic Pulmonary Fibrosis: A Potential Second-Hit Mechanism Linking Intermittent Hypoxia to Fibrotic Progression. · Respiratory medicine 2026 PMID 43020231 on PubMed ↗
- Discovery of YKS-34, a Highly Selective PDE4B Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. · Journal of medicinal chemistry 2026 PMID 43018600 on PubMed ↗
- Lung-Tailored Pyrrolo-pyrimidine DDR Inhibitors Designed for Optimized Local Delivery. · Journal of medicinal chemistry 2026 PMID 43018594 on PubMed ↗
- Inhalable nanodelivery strategies for overcoming the pathological cascade of idiopathic pulmonary fibrosis. · International journal of pharmaceutics 2026 PMID 43014463 on PubMed ↗
- Mesothelial plasticity regulates lung mechanical homeostasis in regeneration and fibrosis. · Developmental cell 2026 PMID 42914979 on PubMed ↗
- Mechanism, Clinical Evidence, and Therapeutic Role of Nerandomilast in Fibrotic Lung Diseases. · Clinical drug investigation 2026 PMID 43009718 on PubMed ↗
- Selective ORgan-targeting lipid nanoparticles deliver SMAD7 mRNA to fibrotic lungs and attenuate pulmonary fibrosis. · Journal of controlled release : official journal of the Controlled Release Society 2026 PMID 43009023 on PubMed ↗
- RNA-binding proteins as emerging regulators in interstitial lung diseases. · American journal of respiratory cell and molecular biology 2026 PMID 43006853 on PubMed ↗
- Targeting the Snail1-ATGL-ferroptosis-EMT axis via AKT-GSK3β signaling: Low-dose colchicine attenuates idiopathic pulmonary fibrosis. · European journal of pharmacology 2026 PMID 42785459 on PubMed ↗
- Pulmonary Fibroblast Heterogeneity and Functional Remodeling in Idiopathic Pulmonary Fibrosis: State Persistence and Reversibility. · International journal of molecular sciences 2026 PMID 43028275 on PubMed ↗
- GPCRAgent: an intelligent multi-agent platform integrating knowledge graphs and large language models for GPCR-targeted drug discovery. · Journal of advanced research 2026 PMID 43003299 on PubMed ↗
- Alive and on Initial Antifibrotic Treatment: Real-World Treatment Durability in Idiopathic and Progressive Pulmonary Fibrosis. · Journal of clinical medicine 2026 PMID 43030854 on PubMed ↗
This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.